Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript

PresentationGood morning, and welcome to the Kyverna Therapeutics Investor Conference Call. [Operator Instructions] Please note that this call is being recorded.Jessica Serra Good morning, and thank you for joining today's conference call to discuss top line data from our KYSA-8 registrational trial of mivocabtagene autoleucel or miv-cel, formerly referred to as KYV-101 in patients with stiff person syndrome or SPS. Before we begin, I encourage everyone to visit the Investor Relations section of our website ...